With greater convenience for patients and reduced geographic, financial, and practical barriers to participation, the pandemic has pushed the industry toward swift adoption of Decentralized Clinical Trials (DCTs). The global health crisis has been a learning experience for patients and sites in ways that nobody could have anticipated. Still, with new forms of communication thrust upon them, people have adopted and thrived. With all that has been learned, it is likely that DCTs will be here to stay long after this terrible virus has been tamed.
Learn more from Roz Round, Parexel’s Vice President, Patient Innovation Center about her firsthand experience with COVID19 and how it reinforced her commitment to DCTs as a way of ensuring patient safety and enabling ongoing trial participation.